Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China-Reference-Cited by-同舟云学术

Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China

Published:2021-12 Issue: Volume:27 Page:67-71
ISSN:2213-7165
Container-title:Journal of Global Antimicrobial Resistance
language:en
Short-container-title:Journal of Global Antimicrobial Resistance

Author:

Kang Yixin,Zhou Qian,Cui Junchang

Publisher

Elsevier BV

Subject

Microbiology (medical),Immunology,Immunology and Allergy,Microbiology

Reference25 articles.

1. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases;Munoz-Price;Lancet Infect Dis,2013

2. Epidemiology of carbapenem-resistant Enterobacteriaceae infections: report from the China CRE Network;Zhang;Antimicrob Agents Chemother,2018

3. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria;Nordmann;Lancet Infect Dis,2009

4. Phenotypic and genotypic characterization of carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012–2016);Wang;Clin Infect Dis,2018

5. Efficacy of ceftazidime–avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae;Alraddadi;BMC Infect Dis,2019

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria;International Journal of Antimicrobial Agents;2024-09

2. Adequacy of the Dosing and Infusion Time of Ceftazidime/Avibactam for the Treatment of Gram-Negative Bacterial Infections: A PK/PD Simulation Study;Infection and Drug Resistance;2024-07

3. Pharmacokinetic parameters of CAZ–AVI in the normal lung and in models of pneumonia: lessons for treatment optimization in critical care;Journal of Chemotherapy;2024-01-30

4. Retrospective Tertiary Care‐Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime‐Avibactam‐Resistant Carbapenem‐Resistant Klebsiella pneumoniae Infections;Critical Care Research and Practice;2024-01

5. All Roads Lead to Rome: Enhancing the Probability of Target Attainment with Different Pharmacokinetic/Pharmacodynamic Modelling Approaches;Antibiotics;2023-04-01